Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations.

Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Coronary artery disease; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 04 Apr 2018 Results (n=48) of post hoc analysis from SUSTAIN and ASSURE trials assessing the effects of pharmacologic epigenetic modulation on levels of ALP and kidney function via apabetalone published in the Kidney and Blood Pressure Research.
    • 15 Nov 2017 Results of ASSERT, SUSTAIN and ASSURE trials assessing presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 12 Oct 2017 Results of a pooled analysis from ASSERT, ASSURE, SUSTAIN trials (n = 798) published in the American Journal of Cardiovascular Drugs
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top